Richard G. Stock, MD

Richard G. Stock, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.

Dr. Stock earned his medical degree and an internship in Internal Medicine from Mount Sinai. He then completed a residency in Internal Medicine at the Beth Israel Medical Center in New York, New York. Dr. Stock then completed a residency in Radiation Oncology at the Memorial Sloan Kettering Cancer Center in New York, New York.

Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society. He also served as a guest editor of a special Brachytherapy issue of Techniques in Urology. Dr. Stock has authored and co-authored over 140 publications and has contributed substantially to the understanding of prostate brachytherapy. Dr. Stock is also a co-investigator on Department of Defense, American Cancer Society, and NIH RO1 grants to study the relationship between genetic mutations and radiation side effects for patients undergoing radiation for prostate cancer.  In a recent publication in the International Journal of Radiation Oncology Biology Physics, Dr. Stock ranked among the top 4% of academic Radiation Oncologists in terms of the h-factor, a surrogate score for research productivity.

Talks by Richard G. Stock, MD

Adjuvant-Salvage Radiotherapy Following Prostatectomy

Adjuvant-Salvage Radiotherapy Following Prostatectomy

| Oct 2023

Richard G. Stock, MD analyzes adjuvant and salvage radiotherapy following prostatectomy in prostate cancer patients with high-risk features or biochemical recurrence post-surgery. Adjuvant radiotherapy is administered shortly after prostatectomy in patients with adverse pathological features, such as positive surgical margins or seminal vesicle invasion, aiming to eradicate microscopic residual disease. Salvage radiotherapy is employed in response to a rising prostate-specific antigen (PSA) level indicating biochemical recurrence after an initial period of undetectable PSA post-surgery.
Dr. Stock reviews pivotal clinical trials and studies, including the SWOG 8794, EORTC 22911, and ARO 96-02 trials, which have demonstrated the efficacy of adjuvant radiotherapy in improving biochemical progression-free survival and overall survival in patients with high-risk features. He highlights the long-term benefits of early intervention with radiotherapy, emphasizing its potential to prevent metastatic progression.

Read More

Combining Therapy with SBRT and Brachytherapy

| Apr 2022

Richard G. Stock, MD, Professor of Radiation Oncology and Director of Genitourinary Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York City, discusses the efficacy of SBRT and brachytherapy for treating patients with prostate cancer. He explains that combined SBRT and brachytherapy seems to be particularly helpful for intermediate-risk cancer, with studies showing about a 90% biochemical control rate. Dr. Stock then goes over the rationale for combined SBRT and brachytherapy, noting that brachytherapy combined with external beam radiation therapy (EBRT) at standard fractionation demonstrates excellent and safe outcomes for both intermediate- and high-risk prostate cancer, and SBRT appears to be comparable or better than standard fractionation without increased toxicity. He summarizes the findings of several different studies, explaining that with low-dose-rate brachytherapy and SBRT, researchers are seeing very similar results to using standard fractionation with brachytherapy. Dr. Stock also looks at a recent trial with high-dose-rate brachytherapy with SBRT which found a favorable early toxicity profile and encouraging cancer control outcomes. He concludes that the combination of SBRT and brachytherapy is promising, and the initial clinical impression is that patients tolerate the treatment well.

Read More
Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?

Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?

| May 2021

Richard G. Stock, MD, Professor of Radiation Oncology and Director of Genitourinary Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York City, reviews the literature on rectal displacement to prevent damage to the rectum from prostate brachytherapy and external beam radiation therapy (EBRT). First, he summarizes the findings of numerous papers from the past 20 years that have identified a relationship between the dose and volume of radiation and damage to the rectum such as bleeding and mucosal changes. The more radiation reaches the rectum, and the greater the surface area of the rectum affected, the more likely patients will experience adverse effects, including greater levels of morbidity. Dr. Stock then considers how the rectum can be spared, focusing on the evidence around rectal spacers such as endorectal balloons and hydrogel spacers such as SpaceOAR. He explains that numerous studies demonstrate that by inserting a physical barrier between the rectum and the prostate, the rectum is kept separate from the radiation and therefore receives a lower rate of toxicity. Dr. Stock notes that patients experience more rectal discomfort with spacers like SpaceOAR than without, but suggests that the reduction of significant issues such as bleeding outweigh the downsides. He concludes by discussing a recent study of his which found that SpaceOAR can be inserted before brachytherapy and EBRT.

Read More